Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors. https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2